T

here’s more than one way to attack PCSK9 and lower cholesterol, but investors seem to be losing hope that the field’s next generation of drugs will ever make a splash on the market.

The Medicines Company, which is years away from selling its PCSK9 drug, saw its share price tumble by about 15 percent on Friday despite presenting positive data, as Wall Street reacted to disappointing clinical results from Amgen’s approved Repatha that have changed the landscape in biotech.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Take your pick:

    -Repatha, lowers LDL cholesterol 59%, for $14,100/year.

    -Vytorin 10/40 (well tolerated), lowers LDL cholesterol 55%, for $25/month with coupon.

    No brainer.

  • This is where the rubber meets the road profit or professional medicine? Somehow I think I’d have a heart attack to hear Jean Luke’s reply when Beverly said we can’t cure WARF our stock holders won’t approve it..

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X